The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia

Abstract

Objective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treatingdiabetic dyslipidemia.Study Design: Comparative cross-sectional study.Place and Duration of Study: The study was conducted at the Department of Biochemistry, Nishtar MedicalUniversity and Hospital Multan, Pakistan over 12 months from January 2021 to January 2022.Methods: Following a 4-week run-in phase, sixty newly diagnosed patients with a previous diagnosis ofdiabetes and dyslipidemia were included. Eligible participants were aged 18-65 years, with fasting triglyceride(TG) levels >200–400 mg/dL and documented type 2 diabetes mellitus (T2DM). Following baselineassessments, participants were randomised into two treatment groups: Saroglitazar 4 mg with 10 mg ofAtorvastatin and Fenofibrate 200 mg with 10 mg of Atorvastatin. Lipid profiles, fasting blood glucose (FBG), andHbA1c were evaluated at baseline and after 12 weeks. Statistical analysis was conducted using appropriatetests with p< 0.05, which is considered significant.Results: The study enrolled 60 participants, with comparable baseline characteristics between groups. Whileboth treatments showed similar effects on lipid profiles, Saroglitazar showed exceptional effectiveness inlowering HbA1c and FBG levels compared to Fenofibrate. No significant differences in adverse effects wereobserved.Conclusion: Saroglitazar may offer advantages in managing diabetic dyslipidemia and improving glycemiccontrol compared to Fenofibrate in a larger sample size. More investigation is necessary to confirm thesefindings and evaluate long-term safety and efficacy. How to cite this: Farooq B, Cheema RR, Qureshi ZH, Yasmeen N, Sahu EH. The Effectiveness and Safety of Fenofibrate and Saroglitazar in The Treatment of Diabetic Dyslipidemia. Life and Science. 2024; 5(2): 266-272. doi: http://doi.org/10.37185/LnS.1.1.632